Drug Discovery & DDS– category –
-
Oral GLP-1 Agonist Elecoglipron Achieves Landmark 11.8% Weight Loss and Superior Glycemic Control in Phase 2 Trial
News-Medical.Net 他 USA Overview The oral GLP-1 receptor agonist elecoglipron delivered compelling results in its Phase 2b SOLSTICE clinical trial, achieving up to 11.8% dose-dependent body weight reduction and significantly improving gl... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe... -
Bispecific Antibody Ivonescimab Plus Chemotherapy Significantly Improves Overall Survival in EGFR-Mutant NSCLC: HARMONi-A Phase 3 Results Published in JAMA
PubMed (JAMA) International Overview Final results from the Phase 3 HARMONi-A clinical trial, published in JAMA, demonstrate a breakthrough in EGFR-mutant non-small cell lung cancer (NSCLC) treatment. Combination therapy with the bispeci... -
Mabwell’s World-First LILRB4/CD3 Bispecific Antibody 6MW5311 Receives FDA Clinical Trial Clearance for Hematologic Malignancies
Mabwell (press release) China Overview Mabwell has secured FDA Clinical Trial Application (CTA) clearance for 6MW5311, a LILRB4/CD3-targeting T-cell engager (TCE) bispecific antibody, for hematologic malignancies including AML, CMML, and... -
Arvinas Accelerates Clinical Development of ARV-027 for Kennedy’s Disease, Targeting Mutant Androgen Receptor Degradation with PROTAC
Kennedy's Disease Association USA Overview Arvinas is steadily advancing the clinical development of ARV-027, an investigational PROTAC degrader for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy, SBMA). ARV-027 is designed to sel... -
University of Houston Discovers ‘Salt-Loaded LNPs’ to Overcome Major Gene Therapy Obstacle by Enhancing Endosomal Escape
University of Houston USA Overview Researchers at the University of Houston have made a groundbreaking discovery to improve intracellular delivery of genetic material, a major hurdle in gene therapy. They developed 'salt-loaded lipid nan... -
Boltz Forms AI Drug Discovery Partnership with Takeda to Boost Molecular Design with Novel Biomolecular Foundation Models
FirstWord HEALTHTECH Japan Overview Boltz has announced a strategic AI drug discovery partnership with Takeda Pharmaceutical Company. This collaboration will integrate Boltz's new biomolecular foundation models, BoltzMol-1 for small mole... -
Novo Nordisk’s Oral Wegovy Approved in UK, Becoming Europe’s First Oral GLP-1 Obesity Treatment
Clinical Research News UK Overview Novo Nordisk's oral GLP-1 receptor agonist, Wegovy (semaglutide tablet), has received approval in the UK, marking its entry as the first oral obesity medication in Europe. This approval is expected to s... -
Antibody-Drug Conjugate (ADC) Field Enters Era of Diversification in 2025: 130 New ADC Candidates Advance to Clinical Development, Total Reaches 2,334
ChemExpress (citing Beacon ADC database) China Overview In 2025, the Antibody-Drug Conjugate (ADC) field experienced a significant paradigm shift, transitioning from platform validation to an era of diversification. The total number of t... -
Solu Therapeutics’ STX-0712 with CyTAC™ Technology Granted FDA Fast Track for Relapsed or Refractory CMML
Pharma News (citing Solu Therapeutics) USA Overview Solu Therapeutics announced that STX-0712, utilizing its CyTAC™ technology, received FDA Fast Track designation for relapsed or refractory chronic myelomonocytic leukemia (CMML). STX-07...
